Primer | Published:

Radiotherapy toxicity

Nature Reviews Disease Primersvolume 5, Article number: 13 (2019) | Download Citation

Abstract

Radiotherapy is used in >50% of patients with cancer, both for curative and palliative purposes. Radiotherapy uses ionizing radiation to target and kill tumour tissue, but normal tissue can also be damaged, leading to toxicity. Modern and precise radiotherapy techniques, such as intensity-modulated radiotherapy, may prevent toxicity, but some patients still experience adverse effects. The physiopathology of toxicity is dependent on many parameters, such as the location of irradiation or the functional status of organs at risk. Knowledge of the mechanisms leads to a more rational approach for controlling radiotherapy toxicity, which may result in improved symptom control and quality of life for patients. This improved quality of life is particularly important in paediatric patients, who may live for many years with the long-term effects of radiotherapy. Notably, signs and symptoms occurring after radiotherapy may not be due to the treatment but to an exacerbation of existing conditions or to the development of new diseases. Although differential diagnosis may be difficult, it has important consequences for patients.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

  • 04 March 2019

    In the version originally published, an incorrect version of Figure 1 was used. This has now been replaced.

References

  1. 1.

    Citrin, D. E. Recent developments in radiotherapy. N. Engl. J. Med. 377, 1065–1075 (2017).

  2. 2.

    Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394-424 (2018).

  3. 3.

    Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

  4. 4.

    Bray, F. et al. CI5 XI. Cancer incidence in five continents volume XI [electronic version]. WHO IARC http://ci5.iarc.fr/CI5-XI (2017).

  5. 5.

    Yap, M. L. et al. Global access to radiotherapy services: have we made progress during the past decade? J. Glob. Oncol. 2, 207–215 (2016).

  6. 6.

    Howlader, N. et al. SEER cancer statistics review, 1975–2010. NIH NCI http://seer.cancer.gov/csr/1975_2010/ (2013).

  7. 7.

    Robison, L. L. et al. Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat. Rev. Cancer. 14, 61–70 (2014).

  8. 8.

    Armstrong, G. T. et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 29, 3056–3064 (2011).

  9. 9.

    Darby, S. C. et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368, 987–998 (2013). This hallmark study shows the relationship between the radiation dose to the heart and mortality in patients with breast cancer.

  10. 10.

    Roychoudhuri, R. et al. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer 7, 9 (2007).

  11. 11.

    Lee, A. W. et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer 123, 4147–4157 (2017). This phase III trial shows the effect of chemotherapy on the outcomes of patients with nasopharyngeal cancer.

  12. 12.

    van Leeuwen, F. E. & Ng, A. K. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am. Soc. Hematol. Educ. Program 2016, 323–330 (2016).

  13. 13.

    Stuschke, M. & Pottgen, C. Altered fractionation schemes in radiotherapy. Front. Radiat. Ther. Oncol. 42, 150–156 (2010).

  14. 14.

    Mahamud, O., So, J., Chua, M. L. K. & Bristow, R. G. Targeting DNA repair for precision radiotherapy: balancing the therapeutic ratio. Curr. Probl. Cancer 41, 265–272 (2017).

  15. 15.

    Morgan, M. A. & Lawrence, T. S. Molecular pathways: overcoming radiation resistance by targeting DNA damage response pathways. Clin. Cancer Res. 21, 2898–2904 (2015).

  16. 16.

    Goldstein, M. & Kastan, M. B. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu. Rev. Med. 66, 129–143 (2015).

  17. 17.

    Pollard, J. M. & Gatti, R. A. Clinical radiation sensitivity with DNA repair disorders: an overview. Int. J. Radiat. Oncol. Biol. Phys. 74, 1323–1331 (2009).

  18. 18.

    Nahas, S. A. & Gatti, R. A. DNA double strand break repair defects, primary immunodeficiency disorders, and ‘radiosensitivity’. Curr. Opin. Allergy Clin. Immunol. 9, 510–516 (2009).

  19. 19.

    Andreassen, C. N., Schack, L. M., Laursen, L. V. & Alsner, J. Radiogenomics — current status, challenges and future directions. Cancer Lett. 382, 127–136 (2016).

  20. 20.

    Foray, N., Bourguignon, M. & Hamada, N. Individual response to ionizing radiation. Mutat. Res. 770, 369–386 (2016).

  21. 21.

    Borgmann, K. et al. in Recent Results in Cancer Research Vol. 198 (eds Baumann, M., Krause, M., Cordes, N.) 1–24 (Springer, 2016).

  22. 22.

    Wu, Q. et al. Modulating both tumor cell death and innate immunity is essential for improving radiation therapy effectiveness. Front. Immunol. 8, 613 (2017). This study shows that immunogenic cell death activates T cell immunity, and activation of the innate immunity is essential to obtain an optimal immune response.

  23. 23.

    Vakifahmetoglu, H., Olsson, M. & Zhivotovsky, B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 15, 1153–1162 (2008).

  24. 24.

    Gudkov, A. V. & Komarova, E. A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 3, 117–129 (2003).

  25. 25.

    Firat, E., Tsurumi, C., Gaedicke, S., Huai, J. & Niedermann, G. Tripeptidyl peptidase II plays a role in the radiation response of selected primary cell types but not based on nuclear translocation and p53 stabilization. Cancer Res. 69, 3325–3331 (2009).

  26. 26.

    Yu, H. et al. Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood 115, 3472–3480 (2010).

  27. 27.

    Paris, F. et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293–297 (2001).

  28. 28.

    Lee, C. L., Blum, J. M. & Kirsch, D. G. Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis. Transl Cancer Res. 2, 412–421 (2013).

  29. 29.

    Venkatesulu, B. P. et al. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl Sci. 3, 563–572 (2018).

  30. 30.

    Bodo, S. et al. Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. J. Clin. Invest. https://doi.org/10.1172/JCI97631 (2018).

  31. 31.

    Moding, E. J. et al. Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy. Sci. Transl Med. 7, 278ra234 (2015).

  32. 32.

    Qiu, W. et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2, 576–583 (2008).

  33. 33.

    Kirsch, D. G. et al. p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 327, 593–596 (2010).

  34. 34.

    Kirsch, D. G. Using genetically engineered mice for radiation research. Radiat. Res. 176, 275–279 (2011).

  35. 35.

    Clevers, H. Searching for adult stem cells in the intestine. EMBO Mol. Med. 1, 255–259 (2009).

  36. 36.

    Potten, C. S., Gandara, R., Mahida, Y. R., Loeffler, M. & Wright, N. A. The stem cells of small intestinal crypts: where are they? Cell Prolif. 42, 731–750 (2009).

  37. 37.

    Tian, H. et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478, 255–259 (2011).

  38. 38.

    Kim, C. K., Yang, V. W. & Bialkowska, A. B. The role of intestinal stem cells in epithelial regeneration following radiation-induced gut injury. Curr. Stem Cell Rep. 3, 320–332 (2017).

  39. 39.

    Komarova, E. A. et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 23, 3265–3271 (2004).

  40. 40.

    Hua, G. et al. Distinct levels of radioresistance in Lgr5(+) colonic epithelial stem cells versus Lgr5(+) small intestinal stem cells. Cancer Res. 77, 2124–2133 (2017).

  41. 41.

    Wilke, C., Grosshans, D., Duman, J., Brown, P. & Li, J. Radiation-induced cognitive toxicity: pathophysiology and interventions to reduce toxicity in adults. Neuro Oncol. 20, 597–607 (2018).

  42. 42.

    Emmerson, E. et al. Salivary glands regenerate after radiation injury through SOX2-mediated secretory cell replacement. EMBO Mol. Med. 10, e8051 (2018).

  43. 43.

    Nehs, M. A. et al. Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers. Surgery 150, 1032–1039 (2011).

  44. 44.

    Castle, K. D. et al. Mice lacking RIP3 kinase are not protected from acute radiation syndrome. Radiat. Res. 189, 627–633 (2018).

  45. 45.

    Hu, B. et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. Science 354, 765–768 (2016).

  46. 46.

    Stoecklein, V. M. et al. Radiation exposure induces inflammasome pathway activation in immune cells. J. Immunol. 194, 1178–1189 (2015).

  47. 47.

    Pitt, J. M., Kroemer, G. & Zitvogel, L. Immunogenic and non-immunogenic cell death in the tumor microenvironment. Adv. Exp. Med. Biol. 1036, 65–79 (2017).

  48. 48.

    Formenti, S. C. & Demaria, S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl Cancer Inst. 105, 256–265 (2013). This article provides insights into the mechanisms of immune activation by radiotherapy.

  49. 49.

    Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y. X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017).

  50. 50.

    Golden, E. B. et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 3, e28518 (2014).

  51. 51.

    Ventura, J. et al. Localized synchrotron irradiation of mouse skin induces persistent systemic genotoxic and immune responses. Cancer Res. 77, 6389–6399 (2017).

  52. 52.

    Peng, Y. et al. Cysteine protease cathepsin B mediates radiation-induced bystander effects. Nature 547, 458–462 (2017).

  53. 53.

    Moding, E. J., Kastan, M. B. & Kirsch, D. G. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat. Rev. Drug Discov. 12, 526–542 (2013).

  54. 54.

    Wirsdorfer, F. & Jendrossek, V. Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades. Radiat. Oncol. 12, 142 (2017).

  55. 55.

    Bickelhaupt, S. et al. Effects of CTGF blockade on attenuation and reversal of radiation-induced pulmonary fibrosis. J. Natl Cancer Inst. 109, 8 (2017).

  56. 56.

    Abdollahi, A. et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925–935 (2005).

  57. 57.

    Bentzen, S. M. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat. Rev. Cancer 6, 702–713 (2006).

  58. 58.

    Khanna, A. DNA damage in cancer therapeutics: a boon or a curse? Cancer Res. 75, 2133–2138 (2015).

  59. 59.

    Hymes, S. R., Strom, E. A. & Fife, C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment. J. Am. Acad. Dermatol. 54, 28–46 (2006).

  60. 60.

    Molls, M., Herrmann, Th., Steinberg, F., & Feldmann, H. J. in Recent Results in Cancer Research Vol. 130 (eds Hinkelbein, W., Bruggmoser, G., Frommhold, H.) 109–121 (Springer, 1993).

  61. 61.

    Trott, K. R., Herrmann, T. & Kasper, M. Target cells in radiation pneumopathy. Int. J. Radiat. Oncol. Biol. Phys. 58, 463–469 (2004).

  62. 62.

    Wynn, T. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199–210 (2008).

  63. 63.

    Rübe, C. E. et al. Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. Strahlenther. Onkol. 180, 442–448 (2004).

  64. 64.

    Ozturk, B., Egehan, I., Atavci, S. & Kitapci, M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 58, 213–219 (2004).

  65. 65.

    Stone, H. B., Peters, L. J. & Milas, L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J. Natl Cancer Inst. 63, 1229–1235 (1979). This paper presents the first preclinical study showing the effect of immunity on the effects of radiotherapy on tumours.

  66. 66.

    Van Limbergen, E. J. et al. Combining radiotherapy with immunotherapy: the past, the present and the future. Br. J. Radiol. 90, 20170157 (2017).

  67. 67.

    Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379, 2342–2350 (2018).

  68. 68.

    Basler, L., Andratschke, N., Ehrbar, S., Guckenberger, M. & Tanadini-Lang, S. Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study. Radiat. Oncol. 13, 10 (2018).

  69. 69.

    Kuo, P. et al. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. Clin. Cancer Res. 20, 5558–5569 (2014).

  70. 70.

    Takeshima, T. et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 70, 2697–2706 (2010).

  71. 71.

    Zhang, X. & Niedermann, G. Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response. Int. J. Radiat. Oncol. Biol. Phys. 101, 63–73 (2018).

  72. 72.

    Marciscano, A. E. et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin. Cancer Res. 24, 5058–5071 (2018).

  73. 73.

    Filatenkov, A. et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin. Cancer Res. 21, 3727–3739 (2015).

  74. 74.

    Morisada, M. et al. PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. Oncoimmunology 7, e1395996 (2018).

  75. 75.

    Schrek, R. & Stefani, S. Radioresistance of phytohemagglutinin-treated normal and leukemic lymphocytes. J. Natl Cancer Inst. 32, 507–521 (1964).

  76. 76.

    Shaverdian, N. et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18, 895–903 (2017).

  77. 77.

    Finn, O. J. The dawn of vaccines for cancer prevention. Nat. Rev. Immunol. 18, 183–194 (2018).

  78. 78.

    Myers, C. J. & Lu, B. Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody correlated with increased T cell infiltration into cardiac and lung tissues. Int. J. Radiat. Oncol. Biol. Phys. 99, 1129–1136 (2017).

  79. 79.

    Burnette, B. C. et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res. 71, 2488–2496 (2011).

  80. 80.

    Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat. Commun. 8, 15618 (2017). This article shows the relationship between the dose per fraction of radiation, the effect on the immune system and the mechanisms for resistance.

  81. 81.

    Fischer, J. C. et al. RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury. Sci. Transl Med. 9, 2513 (2017).

  82. 82.

    Dou, Z. et al. Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature 550, 402–406 (2017).

  83. 83.

    Bijl, H. P. et al. Unexpected changes of rat cervical spinal cord tolerance caused by inhomogeneous dose distributions. Int. J. Radiat. Oncol. Biol. Phys. 57, 274–281 (2003).

  84. 84.

    Defraene, G., van Elmpt, W., Crijns, W., Slagmolen, P. & De Ruysscher, D. CT characteristics allow identification of patient-specific susceptibility for radiation-induced lung damage. Radiother. Oncol. 117, 29–35 (2015).

  85. 85.

    Hartgerink, D. et al. Stereotactic radiosurgery in the management of patients with brain metastases of non-small cell lung cancer: indications, decision tools and future directions. Front. Oncol. 8, 154 (2018).

  86. 86.

    Ellingson, B. M., Chung, C., Pope, W. B., Boxerman, J. L. & Kaufmann, T. J. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J. Neurooncol. 134, 495–504 (2017).

  87. 87.

    Hassanzadeh, C. et al. Multiparametric MRI and [18F]fluorodeoxyglucose positron emission tomography imaging is a potential prognostic imaging biomarker in recurrent glioblastoma. Front. Oncol. 7, 178 (2017).

  88. 88.

    Brown, P. D. et al. Effect of radiosurgery alone versus radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316, 401–409 (2016).

  89. 89.

    Wefel, J. S., Parsons, M. W., Gondi, V. & Brown, P. D. Neurocognitive aspects of brain metastasis. Handb. Clin. Neurol. 149, 155–165 (2018).

  90. 90.

    Moore, D. M., D’Mello, A. M., McGrath, L. M. & Stoodley, C. J. The developmental relationship between specific cognitive domains and grey matter in the cerebellum. Dev. Cogn. Neurosci. 24, 1–11 (2017).

  91. 91.

    Péchoux, C. L. et al. Prophylactic cranial irradiation for patients with lung cancer. Lancet Oncol. 17, e277–e293 (2016).

  92. 92.

    De Ruysscher, D. et al. Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomics. Acta Oncol. 52, 1405–1410 (2013).

  93. 93.

    De Ruysscher, D. et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother. Oncol. 124, 1–10 (2017).

  94. 94.

    Defraene, G., van Elmpt, W., Crijns, W. & De Ruysscher, D. Regional variability in radiation-induced lung damage can be predicted by baseline CT numbers. Radiother. Oncol. 122, 300–306 (2017).

  95. 95.

    Yirmibesoglu, E. et al. Challenges scoring radiation pneumonitis in patients irradiated for lung cancer. Lung Cancer. 76, 350–353 (2012).

  96. 96.

    Billiet, C. et al. Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 stage III-N2 NSCLC after induction chemotherapy and resection. J. Thorac. Oncol. 11, 1940–1953 (2016).

  97. 97.

    Addley, H. C., Vargas, H. A., Moyle, P. L., Crawford, R. & Sala, E. Pelvic imaging following chemotherapy and radiation therapy for gynecologic malignancies. Radiographics 30, 1843–1856 (2010).

  98. 98.

    Diao, K. et al. Radiation toxicity in patients with collagen vascular disease and intrathoracic malignancy treated with modern radiation techniques. Radiother. Oncol. 125, 301–309 (2017).

  99. 99.

    De Ruysscher, D. et al. Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: a preclinical study with a high precision image-guided irradiator. Radiother. Oncol. 124, 482–487 (2017).

  100. 100.

    van Wijk, Y. et al. Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: comparison of dose, toxicity and cost-effectiveness. Radiother. Oncol. 125, 107–112 (2017).

  101. 101.

    Barnett, G. C. et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat. Rev. Cancer 9, 134–142 (2009).

  102. 102.

    Beech, N., Robinson, S., Porceddu, S. & Batstone, M. Dental management of patients irradiated for head and neck cancer. Aust. Dent. J. 59, 20–28 (2014).

  103. 103.

    van Nimwegen, F. A. et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 129, 2257–2265 (2017).

  104. 104.

    Wang, K. et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J. Clin. Oncol. 35, 1387–1394 (2017).

  105. 105.

    Kyriakakis, N. et al. Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours. Clin. Endocrinol. 84, 372–379 (2016).

  106. 106.

    Andreyev, J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. Lancet Oncol. 8, 1007–1017 (2007).

  107. 107.

    Sharma, R. A. et al. Clinical development of new drug-radiotherapy combinations. Nat. Rev. Clin. Oncol. 13, 627–642 (2016).

  108. 108.

    Bennett, M. H., Feldmeier, J., Hampson, N. B., Smee, R. & Milross, C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst. Rev. 4, CD005005 (2016).

  109. 109.

    Bolderston, A., Lloyd, N. S., Wong, R. K., Holden, L. & Robb-Blenderman, L. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support. Care Cancer 14, 802–817 (2006).

  110. 110.

    Schmuth, M. et al. Topical corticosteroid therapy for acute radiation dermatitis: a prospective, randomized, double-blind study. Br. J. Dermatol. 146, 983–991 (2002).

  111. 111.

    Blijlevens, N. M., Donnelly, J. P. & De Pauw, B. E. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 25, 1269–1278 (2000).

  112. 112.

    Blanchard, D. et al. Management of somatic pain induced by head and neck cancer treatment: pain following radiation therapy and chemotherapy. Guidelines of the French Otorhinolaryngology Head and Neck Surgery Society (SFORL). Eur. Ann. Otorhinolaryngol. Head Neck Dis. 131, 253–256 (2014).

  113. 113.

    Epstein, J. B. et al. Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92, 875–885 (2001).

  114. 114.

    Sheibani, K. M. et al. Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac. J. Clin. Oncol. 11, 22–27 (2015).

  115. 115.

    Kazemian, A., Kamian, S., Aghili, M., Hashemi, F. A. & Haddad, P. Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur. J. Cancer Care 18, 174–178 (2009).

  116. 116.

    Miller, R. et al. A phase III, Randomized double-blind study of doxepin rinse versus magic mouthwash versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy (Alliance A221304). Int. J. Radiat. Oncol. Biol. Phys. 96, 938 (2016).

  117. 117.

    Goldgraber, M. B., Rubin, C. E., Palmer, W. L., Dobson, R. L. & Massey, B. W. The early gastric response to irradiation; a serial biopsy study. Gastroenterology 27, 1–20 (1954).

  118. 118.

    Henriksson, R., Bergstrom, P., Franzen, L., Lewin, F. & Wagenius, G. Aspects on reducing gastrointestinal adverse effects associated with radiotherapy. Acta Oncol. 38, 159–164 (1999).

  119. 119.

    Hesketh, P. J., Bohlke, K. & Kris, M. G. Antiemetics: American society of clinical oncology focused guideline update. J. Oncol. Pract. 12, 88–89 (2016).

  120. 120.

    Wong, R. et al. 5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J. Clin. Oncol. 24, 3458–3464 (2006).

  121. 121.

    Misirlioglu, C. H., Demirkasimoglu, T., Kucukplakci, B., Sanri, E. & Altundag, K. Pentoxifylline and alpha-tocopherol in prevention of radiation-induced lung toxicity in patients with lung cancer. Med. Oncol. 24, 308–311 (2007).

  122. 122.

    Abratt, R. P. & Morgan, G. W. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer 35, 103–109 (2002).

  123. 123.

    Jacobson, G. et al. Randomized trial of pentoxifylline and vitamin E versus standard follow-up after breast irradiation to prevent breast fibrosis, evaluated by tissue compliance meter. Int. J. Radiat. Oncol. Biol. Phys. 85, 604–608 (2013).

  124. 124.

    Delanian, S., Porcher, R., Balla-Mekias, S. & Lefaix, J. L. Randomized placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J. Clin. Oncol. 21, 2545–2550 (2003).

  125. 125.

    Graham, M. V. et al. Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 45, 323–329 (1999).

  126. 126.

    Palma, D. A. et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 85, 444–450 (2013).

  127. 127.

    Kwa, S. L. et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int. J. Radiat. Oncol. Biol. Phys. 42, 1–9 (1998).

  128. 128.

    Smith, J. C. Radiation pneumonitis: a review. Am. Rev. Respir. Dis. 87, 647–655 (1963).

  129. 129.

    Ward, H. E., Kemsley, L., Davies, L., Holecek, M. & Berend, N. The effect of steroids on radiation-induced lung disease in the rat. Radiat. Res. 136, 22–28 (1993).

  130. 130.

    Sekine, I. et al. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother. Oncol. 80, 93–97 (2006).

  131. 131.

    Jain, V. & Berman, A. T. Radiation pneumonitis: old problem, new tricks. Cancers 10, E222 (2018).

  132. 132.

    Sodergren, S. C. et al. Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. Support. Care Cancer 23, 3613–3623 (2015).

  133. 133.

    The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol. Med. 28, 551–558 (1998).

  134. 134.

    Siddiqui, F., Liu, A. K., Watkins-Bruner, D. & Movsas, B. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. J. Clin. Oncol. 32, 2920 (2014).

  135. 135.

    Bhat, S. R. et al. Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J. Clin. Oncol. 23, 5493–5500 (2005).

  136. 136.

    Ringash, J. Quality of life in head and neck cancer: where we are, and where we are going. Int. J. Radiat. Oncol. Biol. Phys. 97, 662–666 (2017).

  137. 137.

    Nutting, C. M. et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 12, 127–136 (2011).

  138. 138.

    Rathod, S. et al. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study. Oral Oncol. 49, 634–642 (2013).

  139. 139.

    Pow, E. H. et al. Xerostomia and quality of life after intensity-modulated radiotherapy versus conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 66, 981–991 (2006).

  140. 140.

    Kam, M. K. et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J. Clin. Oncol. 25, 4873–4879 (2007).

  141. 141.

    Kuhlthau, K. A. et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J. Clin. Oncol. 30, 2079 (2012).

  142. 142.

    Pui, C. H. et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 24, 371 (2010).

  143. 143.

    Liang, D. C. et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 24, 397 (2010).

  144. 144.

    Giuliani, M. et al. The prevalence and determinants of return to work in head and neck cancer survivors. Support. Care Cancer 27, 539–546 (2018).

  145. 145.

    Nguyen, N.-T. A. & Ringash, J. Head and neck cancer survivorship care: a review of the current guidelines and remaining unmet needs. Curr. Treat. Options Oncol. 19, 44 (2018).

  146. 146.

    Kerns, S. L. et al. Radiogenomics: the search for genetic predictors of radiotherapy response. Future Oncol. 10, 2391–2406 (2014).

  147. 147.

    Kerns, S. L. et al. Radiation biology and oncology in the genomic era. Br. J Radiol. 91, 20170949 (2018).

  148. 148.

    Brown, P. D. et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 15, 1429–1437 (2013).

  149. 149.

    Bernier, J., Hall, E. J. & Giaccia, A. Radiation oncology: a century of achievements. Nat. Rev. Cancer 4, 737–747 (2004).

  150. 150.

    Giaccia, A. J. Molecular radiobiology: the state of the art. J. Clin. Oncol. 32, 2871–2878 (2014).

  151. 151.

    Moding, E. J., Mowery, Y. M. & Kirsch, D. G. Opportunities for radiosensitization in the stereotactic body radiation therapy (SBRT) era. Cancer J. 22, 267–273 (2016).

  152. 152.

    Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313–322 (2018).

  153. 153.

    Burris, H. A. 3rd & Hurtig, J. Radiation recall with anticancer agents. Oncologist 15, 1227–1237 (2010).

  154. 154.

    Reynders, K., Illidge, T., Siva, S., Chang, J. Y. & De Ruysscher, D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat. Rev. 41, 503–510 (2015).

  155. 155.

    Rodriguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39, 644–655 (2018).

  156. 156.

    Krull, K. R., Hardy, K. K., Kahalley, L. S., Schuitema, I. & Kesler, S. R. Neurocognitive outcomes & interventions in long-term survivors of childhood cancer. J. Clin. Oncol. 36, 2181–2189 (2018).

  157. 157.

    Packer, R. J. et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study. J. Clin. Oncol. 21, 3255–3261 (2003).

  158. 158.

    Bowers, D. C. et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J. Clin. Oncol. 24, 5277–5282 (2006).

  159. 159.

    Haddy, N. et al. Relationship between the brain radiation dose for the treatment of childhood cancer and the risk of long-term cerebrovascular mortality. Brain 134, 1362–1372 (2011).

  160. 160.

    Clement, S. C. et al. Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: a nationwide, multicenter study. J. Clin. Oncol. 34, 4362–4370 (2016).

  161. 161.

    Mostoufi-Moab, S. et al. Endocrine abnormalities in aging survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 34, 3240 (2016).

  162. 162.

    Laughton, S. J. et al. Endocrine outcomes for children with embryonal brain tumors after risk-adapted craniospinal and conformal primary-site irradiation and high-dose chemotherapy with stem-cell rescue on the SJMB-96 trial. J. Clin. Oncol. 26, 1112–1118 (2008).

  163. 163.

    Mertens, A. C. et al. Pulmonary complications in survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Cancer 95, 2431–2441 (2002).

  164. 164.

    Schellong, G. et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for hodgkin disease in children and adolescents: Report from the longitudinal GPOH follow-up project of the German–Austrian DAL-HD studies. Pediatr. Blood Cancer 55, 1145–1152 (2010).

  165. 165.

    van der Pal, H. J. et al. High risk of symptomatic cardiac events in childhood cancer survivors. J. Clin. Oncol. 30, 1429–1437 (2012).

  166. 166.

    de Vathaire, F. et al. Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors: a retrospective cohort study. Lancet Oncol. 13, 1002–1010 (2012).

  167. 167.

    Merchant, T. E. et al. Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59, 556–561 (2004).

  168. 168.

    Paulino, A. C. Late effects of radiotherapy for pediatric extremity sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 60, 265–274 (2004).

  169. 169.

    Meacham, L. R. et al. Diabetes mellitus in long-term survivors of childhood cancer: increased risk associated with radiation therapy: a report for the childhood cancer survivor study. Arch. Intern. Med. 169, 1381–1388 (2009).

  170. 170.

    Goldsby, R. et al. Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology 140, 1464–1471 (2011).

  171. 171.

    Castellino, S. et al. Hepato-biliary late effects in survivors of childhood and adolescent cancer: a report from the Children’s Oncology Group. Pediatr. Blood Cancer 54, 663–669 (2010).

  172. 172.

    Wasilewski-Masker, K. et al. Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study. J. Cancer Surviv. 8, 437–447 (2014).

  173. 173.

    Signorello, L. B. et al. Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet 376, 624–630 (2010).

  174. 174.

    Tukenova, M. et al. Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment. Cancer Epidemiol. Biomarkers Prev. 19, 707–715 (2010).

  175. 175.

    Journy, N. et al. Volume effects of radiotherapy on the risk of second primary cancers: a systematic review of clinical and epidemiological studies. Radiother. Oncol. https://doi.org/10.1016/j.radonc.2018.09.017 (2018).

  176. 176.

    Chang, E. L. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, 1037–1044 (2009).

  177. 177.

    Eckel, R. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365, 1415–1428 (2005).

  178. 178.

    Nottage, K. A. et al. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia — from the St. Jude Lifetime Cohort. Br. J. Haematol. 165, 364–374 (2014).

  179. 179.

    Hasegawa, H. et al. A comprehensive study of symptomatic late radiation-induced complications after radiosurgery for brain arteriovenous malformation: incidence, risk factors, and clinical outcomes. World Neurosurg. 116, e556–e565 (2018).

  180. 180.

    Appelman-Dijkstra, N. M. et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 96, 2330–2340 (2011).

  181. 181.

    Curran Jr, W. J. et al. Sequential versus concurrent chemoradiation for stage III non–small cell lung cancer: randomized phase III trial RTOG 9410. J. Natl Cancer Inst. 103, 1452–1460 (2011).

  182. 182.

    Cutter, D. J. et al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. J. Natl. Cancer Inst. 107, djv008 (2015).

  183. 183.

    Speirs, C. K. et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non–small cell lung cancer. J. Thorac. Oncol. 12, 293–301 (2017).

  184. 184.

    Greenfield, D. et al. Metabolic syndrome is common following haematopoietic cell transplantation (HCT) and is associated with increased cardiovascular disease: an EBMT cross-sectional non-interventional study [abstract O154]. Bone Marrow Transplant. 50, S89–S90 (2015).

  185. 185.

    Ståhl, O. et al. Sperm DNA integrity in testicular cancer patients. Hum. Reprod. 21, 3199–3205 (2006).

  186. 186.

    Shalet, S. M., Tsatsoulis, A., Whitehead, E. & Read, G. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J. Endocrinol. 120, 161–165 (1989).

  187. 187.

    Howell, S. J. & Shalet, S. M. Spermatogenesis after cancer treatment: damage and recovery. J. Natl Cancer Inst. Monogr. 2005, 12–17 (2005).

  188. 188.

    Groot, H. J. et al. Risk of diabetes after para-aortic radiation for testicular cancer. Br. J. Cancer 119, 901–907 (2018).

  189. 189.

    Al-Mamgani, A., van Putten, W. L., van der Wielen, G. J., Levendag, P. C. & Incrocci, L. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96–10 trial). Int. J. Radiat. Oncol. Biol. Phys. 79, 1004–1012 (2011).

  190. 190.

    Pollack, A. et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 53, 1097–1105 (2002).

  191. 191.

    Zietman, A. L. et al. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294, 1233 (2005).

  192. 192.

    Jakubowicz, J. et al. Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer. Eur. J. Gynaecol. Oncol. 35, 393–399 (2014).

  193. 193.

    Loren, A. W. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31, 2500 (2013).

  194. 194.

    Wallace, W. H. B., Thomson, A. B., Saran, F. & Kelsey, T. W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int. J. Radiat. Oncol. Biol. Phys. 62, 738–744 (2005).

  195. 195.

    Critchley, H. O. & Wallace, W. H. B. Impact of cancer treatment on uterine function. J. Natl Cancer Inst. Monogr. 2005, 64–68 (2005).

  196. 196.

    Teh, W. T., Stern, C., Chander, S. & Hickey, M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res. Int. 2014, 482968 (2014).

  197. 197.

    Xie, L., Lin, C., Zhang, H. & Bao, X. Second malignancy in young early-stage breast cancer patients with modern radiotherapy: a long-term population-based study (a STROBE-compliant study). Medicine 97, e0593 (2018).

  198. 198.

    Rombouts, A. J. M. et al. Does pelvic radiation increase rectal cancer incidence? A systematic review and meta-analysis. Cancer Treat. Rev. 68, 136–144 (2018).

Download references

Reviewer information

Nature Reviews Disease Primers thanks Z. Liao, J. Lucas and the other anonymous reviewer(s), for their contribution to the peer review of this work.

Author information

Affiliations

  1. Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), School for Oncology and Developmental Biology (GROW), Maastricht, Netherlands

    • Dirk De Ruysscher
  2. Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    • Gabriele Niedermann
  3. German Cancer Consortium (DKTK), partner site Freiburg, and German Cancer Research Centre (DKFZ), Heidelberg, Germany

    • Gabriele Niedermann
  4. The Christie, Department of Radiation Oncology, Division of Cancer Sciences, University of Manchester, Manchester, UK

    • Neil G. Burnet
  5. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

    • Shankar Siva
    •  & Fiona Hegi-Johnson
  6. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia

    • Shankar Siva
    •  & Fiona Hegi-Johnson
  7. Department of Clinical Oncology, The University of Hong Kong and The University of Hong Kong–Shenzhen Hospital, Hong Kong, China

    • Anne W. M. Lee
  8. School of Mathematical and Physical Sciences, The University of Newcastle (UON), Newcastle, New South Wales, Australia

    • Fiona Hegi-Johnson

Authors

  1. Search for Dirk De Ruysscher in:

  2. Search for Gabriele Niedermann in:

  3. Search for Neil G. Burnet in:

  4. Search for Shankar Siva in:

  5. Search for Anne W. M. Lee in:

  6. Search for Fiona Hegi-Johnson in:

Contributions

Introduction (D.D.R.); Epidemiology (D.D.R. and F.H.-J.); Mechanisms/pathophysiology (D.D.R. and G.N.); Diagnosis, screening and prevention (D.D.R. and N.G.B.); Management (D.D.R. and S.S.); Quality of life (D.D.R., A.W.M.L and F.H.); Outlook (D.D.R.); Overview of the Primer (D.D.R.).

Competing interests

D.D.R. has served on advisory boards for AstraZeneca, Bristol-Meyers-Squibb, Celgene, Merck Serono/Pfizer and Genentech and has received research grants from Bristol-Meyers-Squibb and Boehringer Ingelheim. No personal fees were received, only fees to the institution. The remaining authors declare no competing interests.

Corresponding author

Correspondence to Dirk De Ruysscher.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41572-019-0064-5